<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03314922</url>
  </required_header>
  <id_info>
    <org_study_id>INCB 50465-111/CITADEL-111</org_study_id>
    <secondary_id>Parsaclisib</secondary_id>
    <nct_id>NCT03314922</nct_id>
  </id_info>
  <brief_title>A Study of INCB050465 in Japanese Subjects With Previously Treated B-Cell Lymphoma (CITADEL-111)</brief_title>
  <official_title>A Phase 1b, Open-Label, Dose-Escalation Study for the Safety, Tolerability, and Pharmacokinetics of INCB050465 in Japanese Subjects With Previously Treated B-Cell Lymphoma (CITADEL-111)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Incyte Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Incyte Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of
      parsaclisib in the treatment of Japanese participants diagnosed with previously-treated
      B-cell lymphoma.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 5, 2018</start_date>
  <completion_date type="Anticipated">July 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment-emergent adverse events (TEAEs)</measure>
    <time_frame>Up to approximately 1 year</time_frame>
    <description>TEAE defined as any adverse event either reported for the first time or worsening of a pre-existing event after first dose of study drug.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in pharmacodynamic (PD) markers of B-cell activation in plasma</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Markers of B-cell activation (eg, B-cell activating factor, interleukin-10, B-cell attracting chemokine) and other plasma analytes will be analyzed for correlation with safety and clinical outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>Up to approximately 1 year</time_frame>
    <description>Defined as the percentage of subjects with complete response (CR)/complete metabolic response (CMR) and partial response (PR)/ partial metabolic response (PMR), as determined by investigator assessment of response according to response criteria for lymphomas.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>Up to approximately 1 year</time_frame>
    <description>Defined as the time from first documented evidence of CR/CMR or PR/PMR until disease progression or death from any cause among subjects who achieve an objective response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Up to approximately 1 year</time_frame>
    <description>Defined as the time from the date of the first dose of study drug until the earliest date of disease progression or death from any cause.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Parsaclisib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Parsaclisib</intervention_name>
    <description>Parsaclisib administered orally once daily for 8 weeks at the protocol-defined dose, followed by a once-weekly regimen at the same dose.</description>
    <arm_group_label>Parsaclisib</arm_group_label>
    <other_name>INCB050465</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  First generation Japanese; subject was born in Japan and has not lived outside of
             Japan for &gt; 10 years, and subject can trace maternal and paternal Japanese ancestry.

          -  Histologically confirmed aggressive/indolent DLBCL, FL, MZL, or MCL.

          -  Previously received at least 1 prior line of systemic therapy with documented
             progression, and there is no further effective standard anticancer therapy available.

          -  Willing to undergo an incisional or excisional lymph node or tissue biopsy or to
             provide a lymph node or tissue biopsy from the most recent available archival tissue.

          -  Life expectancy &gt; 3 months.

          -  Eastern Cooperative Oncology Group performance status of 0 to 2.

          -  Adequate hematologic, hepatic, and renal function.

        Exclusion Criteria:

          -  Evidence of transformed non-Hodgkin's lymphoma histologies.

          -  Histologically confirmed, rare non-Hodgkin's B-cell subtypes.

          -  History of central nervous system lymphoma (either primary or metastatic) or
             leptomeningeal disease.

          -  Prior treatment with idelalisib, other selective PI3KÎ´ inhibitors, or a
             pan-phosphatidylinositol 3 kinase (PI3K) inhibitor.

          -  Allogeneic stem cell transplant within the last 6 months or autologous stem cell
             transplant within the last 3 months before the date of the first dose of study drug.

          -  Active graft-versus-host disease.

          -  History of stroke or intracranial hemorrhage within 6 months of study drug
             administration.

          -  Chronic or current active infectious disease requiring systemic antibiotics,
             antifungal, or antiviral treatment or exposure to a live vaccine within 30 days of the
             date of the first dose of study drug.

          -  Known human immunodeficiency virus infection.

          -  Evidence of hepatitis B virus or hepatitis C virus infection or risk of reactivation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cinthya Coronado, MD</last_name>
    <role>Study Director</role>
    <affiliation>Incyte Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Hospital Organization Kyushu Cancer Center</name>
      <address>
        <city>Fukuoka-shi</city>
        <state>Fukuoka</state>
        <zip>811-1395</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tohoku University Hospital</name>
      <address>
        <city>Sendai-shi</city>
        <state>Miyagi</state>
        <zip>980-8574</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nagoya City University Hospital</name>
      <address>
        <city>Nagoya</city>
        <state>Mizuho-ku</state>
        <zip>467-8602</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aichi Cancer Center</name>
      <address>
        <city>Chikusa-KU</city>
        <state>Nagoya</state>
        <zip>464-8681</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Center</name>
      <address>
        <city>Chuo Ku</city>
        <state>Tokyo</state>
        <zip>104-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>October 16, 2017</study_first_submitted>
  <study_first_submitted_qc>October 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2017</study_first_posted>
  <last_update_submitted>July 14, 2020</last_update_submitted>
  <last_update_submitted_qc>July 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diffuse large B-cell lymphoma (DLBCL)</keyword>
  <keyword>follicular lymphoma (FL)</keyword>
  <keyword>marginal zone lymphoma (MZL)</keyword>
  <keyword>mantle cell lymphoma (MCL)</keyword>
  <keyword>phosphatidylinositol 3-kinase (PI3K)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data will be made available at the end of trial or termination of trial. The following data will be made available: safety, PK and PD, efficacy, and subject characteristics. The results of the trial will be published. In addition, data as documented in study CSR will be made available upon request.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

